SC
ZVRA icon

Sculptor Capital’s Zevra Therapeutics ZVRA Stock Holding History

Sculptor Capital’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-13,700
Closed -$176K – 1024
2021
Q2 		$176K Hold
13,700
– – ﹤0.01% 772
2021
Q1 		$126K Buy
+13,700
New +$120K ﹤0.01% 616

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Sculptor Capital's ZVRA Position: Q3 2021 in Review

Sculptor Capital sold out of Zevra Therapeutics (ZVRA) in Q3 2021, closing a stake of 13,700 shares — an estimated $176K sold.

Sculptor Capital first reported a position in ZVRA in Q1 2021 and held it in 2 quarters. The position peaked at $176K in Q2 2021. 71 funds tracked by Wall St. Rank hold ZVRA as of Q3 2021.

  • Sculptor Capital reported no remaining Zevra Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Sculptor Capital sold 13,700 Zevra Therapeutics shares in Q3 2021, an estimated $176K.
  • Sculptor Capital first reported a position in Zevra Therapeutics in Q1 2021 and held it in 2 quarters.
  • Sculptor Capital's Zevra Therapeutics position peaked at $176K in Q2 2021.
  • 71 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q3 2021.

Based on Sculptor Capital's 13F filing for Q3 2021, filed 12 Nov 2021.